biostudies-literatureUnknown20(1)Vo JBThe Young Women’s Breast Cancer Study is funded in part by Susan G. Komen and Breast Cancer Research FoundationCancer Prevention Fellowship Program at the National Cancer InstituteNational Cancer Institute<h4>Purpose</h4>Data evaluating cardiovascular disease (CVD) risk by cancer treatment among young women (≤ 40 years) with breast cancer are limited.<h4>Methods</h4>Among 372 five-year breast cancer survivors aged 30-40 years from the Young Women's Breast Cancer Study, we assessed the association of cancer treatments (anthracyclines, trastuzumab, radiation/laterality, endocrine therapy) and excess heart age (difference between predicted 10-year CVD risk as assessed by adapted Framingham Risk Score and chronological age), prevalent elevated excess heart age (≥ 2 years), and worsening excess heart age (change of ≥ 2 excess heart age years) at breast cancer diagnosis and two- and five-year follow-up using multivariable linear and logistic regressions.<h4>Results</h4>Most women had stage I or IJournal of cancer survivorship : research and practice189-197https://www.ebi.ac.uk/biostudies/studies/S-EPMC12906554biostudies-literatureAssociation of cancer treatment with excess heart age among five-year young breast cancer survivors.PMC12906554Snow CSchapira LPoorvu PDKirkner GRosenberg SPeppercorn JMVo JBGaither RBorges VFCome SENohria APartridge AHTamimi RMZhang BXRuddy KJfalseAssociation of cancer treatment with excess heart age among five-year young breast cancer survivors.<h4>Purpose</h4>Data evaluating cardiovascular disease (CVD) risk by cancer treatment among young women (≤ 40 years) with breast cancer are limited.<h4>Methods</h4>Among 372 five-year breast cancer survivors aged 30-40 years from the Young Women's Breast Cancer Study, we assessed the association of cancer treatments (anthracyclines, trastuzumab, radiation/laterality, endocrine therapy) and excess heart age (difference between predicted 10-year CVD risk as assessed by adapted Framingham Risk Score and chronological age), prevalent elevated excess heart age (≥ 2 years), and worsening excess heart age (change of ≥ 2 excess heart age years) at breast cancer diagnosis and two- and five-year follow-up using multivariable linear and logistic regressions.<h4>Results</h4>Most women had stage I or I2026-01-01T00:00:00Z2026 Feb2026-07-16T00:08:10.227Z2026-07-09T10:25:53.013ZS-EPMC129065543900813810.1007/s11764-024-01645-9